Beijing Scitop Bio-tech Co: 9M earnings fell sharply as revenue stayed nearly flat and spending rose

What happened

Q3 revenue declined 6.63% year over year and net income fell 69.57%, while nine-month net income dropped 53.10% on nearly flat revenue. Completion of a factory and research center raised expenses, and share repurchases totaled RMB90.77m through September.

Confirmed

Global impact / market context

Profit fell much faster than sales because newly completed buildings add costs such as depreciation before they generate enough revenue, which means profit per sale shrinks. This pressure could persist until new factory and research capacity is used more fully.

Analyst inference

The company is spending on factories and research while sales stall and profit drops. Investors may question how long cash available will fund operations and buybacks, and whether the new capacity can lift revenue before borrowing needs or a slowdown in repurchases becomes necessary.

Analyst inference

What to watch

1. Share repurchases reached RMB90.77m through September, so watch whether the company continues buying shares at this pace or slows spending to preserve cash. Confirmed
2. Watch whether management discloses plans to use the finished factory and research center, since higher output or new products could eventually spread fixed costs over more sales. Proposed
3. Watch upcoming revenue for signs that the sales decline is easing; without a rebound, rising depreciation and research costs could keep net income under pressure. Analyst inference

Evidence

• Original source link unavailable